These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21205142)

  • 1. Chronic hepatitis B: peginterferon or nucleos(t)ide analogues?
    Sonneveld MJ; Janssen HL
    Liver Int; 2011 Jan; 31 Suppl 1():78-84. PubMed ID: 21205142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
    Buster EH; Schalm SW; Janssen HL
    Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?
    Viganò M; Invernizzi F; Lampertico P
    Liver Int; 2015 Jan; 35 Suppl 1():107-13. PubMed ID: 25529095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
    Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?
    Rijckborst V; Sonneveld MJ; Janssen HL
    Aliment Pharmacol Ther; 2011 Mar; 33(5):501-13. PubMed ID: 21198707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues.
    Papatheodoridis GV
    Liver Int; 2011 Jan; 31 Suppl 1():95-103. PubMed ID: 21205145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
    Viganò M; Mangia G; Lampertico P
    Liver Int; 2014 Feb; 34 Suppl 1():120-6. PubMed ID: 24373088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
    Jansen L; Kootstra NA; van Dort KA; Takkenberg RB; Reesink HW; Zaaijer HL
    J Infect Dis; 2016 Jan; 213(2):224-32. PubMed ID: 26216905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?
    Vlachogiannakos J; Papatheodoridis GV
    Liver Int; 2015 Jan; 35 Suppl 1():100-6. PubMed ID: 25529094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs?
    Buti M
    Liver Int; 2014 Feb; 34 Suppl 1():108-11. PubMed ID: 24373086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog.
    Chen X; Cao Z; Liu Y; Zhang H; Zhang Y; Ma L; Jin Y; Yu H; Ma B; Zheng Y; Wu H
    J Gastroenterol Hepatol; 2012 Mar; 27(3):481-6. PubMed ID: 22098411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Interferon in hepatitis B].
    García Buey L; González Mateos F; Moreno Otero R
    Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 7():19-31. PubMed ID: 19100228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of NKG2C+ natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB.
    Yan W; Wu D; Wang X; Chen T; Lai Q; Zheng Q; Jiang J; Hou J; Han M; Ning Q
    Antivir Ther; 2015; 20(6):591-602. PubMed ID: 25814467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interferon-based versus direct antiviral therapy in patients with chronic hepatitis B].
    Tornai I
    Orv Hetil; 2011 May; 152(22):869-74. PubMed ID: 21565754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P; Lenci I; Demelia L; Bandiera F; Piras MR; Antonucci G; Nosotti L; Mari T; De Santis A; Ponti ML; Sorbello O; Iacomi F; Angelico M
    Antivir Ther; 2009; 14(8):1165-74. PubMed ID: 20032546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New developments in the treatment of chronic hepatitis B.
    Hadziyannis SJ
    Expert Opin Biol Ther; 2006 Sep; 6(9):913-21. PubMed ID: 16918258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical therapy of patients affected by HBeAg-negative chronic hepatitis B.
    Marcellin P; Boyer N; Asselah T
    Minerva Gastroenterol Dietol; 2006 Mar; 52(1):23-38. PubMed ID: 16554704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues.
    Leung N
    Liver Int; 2011 Jan; 31 Suppl 1():85-9. PubMed ID: 21205143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy.
    Matsumoto A; Nishiguchi S; Enomoto H; Kang JH; Tanaka Y; Shinkai N; Kurosaki M; Enomoto M; Kanda T; Yokosuka O; Yatsuhashi H; Nagaoka S; Okuse C; Kagawa T; Mine T; Takaguchi K; Saito S; Hino K; Ikeda F; Sakisaka S; Morihara D; Miyase S; Tsuge M; Chayama K; Hiramatsu N; Suzuki Y; Murata K; Tanaka E
    J Gastroenterol; 2018 Feb; 53(2):247-257. PubMed ID: 28634723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression?
    Buster EH; Janssen HL
    Neth J Med; 2006 Jun; 64(6):175-85. PubMed ID: 16788215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.